Sheba researcher: Antiparasitic drug reduces length of COVID-19 infection
According to his yet to be published data, Schwartz said that the drug was shown to help “cure” people of the virus within just six days.
The double-blind, placebo-controlled study included 100 people with mild to moderate cases of the disease who were not hospitalized for the virus. It tested whether ivermectin could shorten the viral shedding period, allowing them to test negative for coronavirus and leave isolation in only a few days.
According to his still unpublished data, Schwartz said the drug was shown to help “cure” people of the virus within just six days. Moreover, the chances of testing negative for coronavirus were three times higher for the group who received ivermectin than the placebo, he told The Jerusalem Post.
“From a public-health point of view, the majority of patients with corona are mild cases, and 90% of these people are isolated outside of the hospital,” Schwartz said. “If you have any kind of drug that can shorten the duration of the infectiousness of these patients, that would be dramatic, as then they will not infect others.”
In addition https://covid19criticalcare.com/ reports:
NIH (National Institutes of Health) Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Ivermectin is Now a Treatment Option for Health Care Providers!
Jan 14, 2021 – One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line COVID-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation and now considers ivermectin an option for use in COVID-19.
Their recommendation has now been upgraded to the same level as those for widely used monoclonal antibodies & convalescent plasma, which is a “neither for nor against” recommendation. The significance of this change is that the NIH has decided to no longer recommend against the use of ivermectin in the treatment of COVID-19 by the nation’s health care providers. A consequence of this change is that ivermectin has now been made a clear therapeutic option for patients.
Read our Press Release (Jan 15) and our Detailed response to the panel’s criticism of the existing evidence base (Jan 17).